Pharmacogenetic aspects of the efficacy and safety profile of H1-histamine receptor blockers in the treatment of allergic diseases
https://doi.org/ 10.24411/2588-0527-2018-10003
Abstract
Today it is known that the second-generation Hl-antihistamines are substrates for the P-glycoprotein, that is encoded by the multiple drug resistance gene. The metabolism of the second-generation Hl-antihistamines involves a number of cytochrome P450 isoenzymes that encoded by the corresponding genes. All these noted genes are polymorphic, that can affect the activity of encoded proteins. Efflux alteration of second-generation Hl-antihistamines, as well as modifications in their biotransformation, can affect their efficacy and safety. The purpose of this review was to generalize current available information about pharmacogenetic characteristics of second-generation Hl-antihistamines and to suspect interindividual variability mechanisms of their efficacy and safety for allergic diseases.
About the Authors
A. K. Zastrozhina
Children’s state polyclinic No. 42 of the Moscow Department of health
Russian Federation
Russian Federation
D. A. Suchev
Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare
Russian Federation
Russian Federation
References
1. Bousquet J., Reid J., van Weel C., et al. Allergic rhinitis management pocket reference 2008. Allergy. 2008 Aug;63(8):990-996. DOI: 10.1111/j.1398-9995.2008.01642.x
2. Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA(2) LEN/EDF/ WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014 Jul;69(7): 868-887. DOI: 10.1111/all.12313
3. Powell RJ, Du Toit GL, Siddique N., et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007 May;37(5): 631-650. DOI: 10.1111/j.1365-2222.2007.02678.x
4. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J. Allergy Clin Immunol. 2008 Aug;122(2 Suppl):S1-84. DOI: 10.1016/j.jaci.2008.06.003
5. Simons FE. Advances in H1-antihistamines. N. Engl J. Med. 2004 Nov 18;351(21):2203-2217. DOI: 10.1056/NEJMra033121
6. Woosley RL. Cardiac Actions of Antihistamines. Annu Rev Pharmacol Toxicol. 1996;36:233-252. DOI: 10.1146/annurev.pa.36.040196.001313
7. Renwick AG. Metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy. 1999 Jul;29 Suppl 3: 116-124.
8. Slater JW, Zechnich AD, Haxby DG. Second-Generation Antihistamines. Drugs. 1999 Jan;57(1):31-47.
9. Church MK, Maurer M., Simons FE, et al. Global Allergy and Asthma European Network. Risk of first-generation H(1)-antihistamines: a GA(2) LEN position paper. Allergy. 2010 Apr;65(4):459-466. DOI: 10.1111/j.1398-9995.2009.02325.x
10. Jauregui I., Ferrer M., Montoro J., et al. Antihistamines in drivers, aircrew and occupations of risk. JInvestig Allergol Clin Immunol. 2013; 23 Suppl 1:27-34.
11. Kubo N., Shirakawa O., Kuno T., et al. Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay. Jpn J. Pharmacol. 1987 Mar;43(3):277-282.
12. Гущин И.С. Антигистаминные препараты. Пособие для врачей. - М.: Авентис Фарма; 2000.
13. Коровина Н.А., Чебуркин А.В., Захарова И.Н., и др. Антигистаминные препараты в практике детского врача. Руководство для врачей. - М.: гОу ДПУ РМАПО Росздрава; 2001.
14. Лусс Л.В. Выбор антигистаминных препаратов в лечении аллергических и псевдоаллергических реакций // Российский аллергологический журнал. - 2009. - № 1. - С.78-84.
15. Ring G., Brockow K., Ollert M., et al. Anttihistamines in urticaria. Clin Exp Allergy. 1999 Mar;29 Suppl 1: 31-37.
16. Konstantinou GN, Asero R., Maurer M., et al. EAACI/ GA2LEN Task force consensus report: the autologous serum skin test in urticarial. Allergy. 2009 Sep;64(9):1256-1268. DOI: 10.1111/j.1398-9995.2009.02132.x
17. Ключарова А.Р. Скороходкина О.В. Сравнительная оценка эффективности и безопасности терапии хронической крапивницы антигистаминными препаратами II поколения // Практическая Медицина. - 2012. - 2(57). - С. 204-207.
18. Колхир П.В., Игнатьев И.В., Сычев Д.А., и др. Влияние носительства генотипов по полиморфному маркеру С3435Т гена MDR1, кодирующего гликопротеид-P, на фармакокинетику блокатора Н1-ги-стаминовых рецепторов III поколения фексофенадина // Аллергология и иммунология. - 2006. - Т. 7. - № 3. - С. 279a-279.
19. Rodrlguez-Gômez SJ, Zamora-Martlnez T., Bailador-Andrés C., et al. Severe intrahepatic cholestasis associated with cetirizine (in Spanish). Gastroenterol Hepatol. 2009 May;32(5):383-384. DOI: 10.1016/j.gastrohep.2009.01.175
20. Fong DG, Angulo P., Burgart LJ, et al. Cetirizine-induce cholestasis. J. Clin Gastroenterol. 2000 Oct;31(3):250-253.
21. Abernethy DR, Barbey JT, Franc J., et al. Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation. Clin Pharmacol Ther. 2001 Mar;69(3):96-103. DOI: 10.1067/mcp.2001.114230
22. Humphreys F., Hunter JA. The characteristics of urticaria in 390 patients. Br J. Dermatol. 1998 Apr;138(4):635-638.
23. Maurer M., Weller K., Bindslev-Jensen C., et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy. 2011 Mar;66(3):317-330. DOI: 10.1111/j.1398-9995.2010.02496.x
24. Sanchez-Borges M., Caballero-Fonseca F., Capriles-Hulett A. Treatment of recalcitrant chronic urticaria with nonsedating antihistamines: is there evidence for updosing? J. Investig Allergol Clin Immunol. 2013; 23(3):141-144; quiz 2 p preceding 145
25. Staevska M., Popov TA, Kralimarkova T., et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J. Allergy Clin Immunol. 2010 Mar;125(3):125:676- 682. DOI: 10.1016/j.jaci.2009.11.047
26. Сычёв Д.А., Игнатьев И.В., Раменская Г.В., и др. Значение полиморфизма гена MDR1, кодирующего гликопротеин-Р, для индивидуализации фармакотерапии // Клиническая Фармакология и Терапия. - 2005. - 14(1). - С. 1-5.
27. Ташенова А.И. Транспортная система гликопротеина-Р и фармакокинетика лекарственных средств // Биомедицина. - 2010. - № 4. - С. 24-32.
28. Wessler JD, Grip LT, Mendell J., et al. The P-glycoprotein transport system and cardiovascular drugs. J. Am Coll Cardiol. 2013 Jun 25;61(25):2495- 2502. DOI: 10.1016/j.jacc.2013.02.058
29. Chen C., Hanson E., Watson JW, et al. Pglycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003 Mar;31(3):312-318.
30. Chishty M., Reichel A., Siva J., et al. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J. Drug Target. 2001 Jun;9(3):223-228.
31. Cvetkovic M., Leake B., Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-871.
32. Ohashi R., Kamikozawa Y., Sugiura M., et al. Effect of P-glycoprotein on intestinal adsorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metab Dispos. 2006; May;34(5):793-799. DOI: 10.1124/dmd.105.007559
33. Polli JW, Baughman TM, Humphreys JE, et al. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. J. Pharm Sci. 2003 Oct;92(10):2082-2089. DOI: 10.1002/jps.10453
34. Wang EJ, Casciano CN, Clement RP, et al. Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001 Aug;29(8):1080-1083.
35. Omote H., Al-Shawi MK. Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism. Biophys J. 2006 Jun 1;90(11):4046-4059.
36. Ambudkar SV, Kimchi-Sarfaty C., Sauna ZE, et al. P-glycoprotein: from genomics to mechanism. Oncogene. 2003 Oct 20;22(47):7468-7485. DOI: 10.1038/sj.onc.1206948
37. Yi SY, Hong KS, Lim HS, et al. A variant 2677a allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther. 2004 Nov;76(5):418-427.
38. Xiong Y., Yuan Z., Yang J., et al. CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers. Eur J. Drug Metab Pharmacokinet. 2016 Apr;41(2):117-124. DOI: 10.1007/s13318-014-0236-3
39. Alzoubi KH, Khabour OF, Al-Azzam SI, et al. The role of multidrug resistance-1 (MDR1) variants in response to fexofenadine among Jordanians. Int JClin Pharmacol Ther. 2013 Nov;51(11):880-887. DOI: 10.5414/CP201968
40. Conen S., Theunissen EL, Vermeeren A., et al. The role of P-glycoprotein in CNS antihistamine effects. Psychopharmacology (Berl.). 2013 Sep;229(1):9-19. DOI: 10.1007/s00213-013-3075-z
41. Lewis DFV. Guide to cytochromes P450. Structure andfunction. London and New York: Taylor & Francis; 2001.
42. Pelkonen O., Turpeinen M., Hakkola J., et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol. 2008 Oct;82(10):667-715. DOI: 10.1007/s00204-008-0332-8
43. Клиническая фармакогенетика: Учебное пособие / Под ред. В.Г. Кукеса, Н.П. Бочкова. - М.: ГЭОТАР Медиа; 2007.
44. Кинетика и динамика пребывания токсических соединений в организме: учебное пособие / В.А. Вавилин и др.; Федеральное агентство по образованию, Новосибирский гос. ун-т, Фак. естественных наук, Каф. химии окружающей среды, Ин-т молекулярной биологии и биофизики СО РАМН. - Новосибирск: Новосибирский гос. ун-т; 2008.
45. Nebert DW, Russell DW. Clinical importance of the cytochrome P450. Lancet. 2002 Oct 12;360(9340):1155-1162. DOI: 10.1016/S0140-6736(02)11203-7
46. Yin OQ, Shi XJ, Tomlinson B., et al. Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. Drug Metab Dispos. 2005 Sep;33(9):1283-1287. DOI: 10.1124/dmd.105.005025.
47. Saruwatari J., Matsunaga M., Ikeda K., et al. Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia. Eur J. Clin Pharmacol. 2006 Dec;62(12):995-1001. DOI: 10.1007/s00228-006-0210-3
48. Palikhe NS, Kim S., Ye Y., et al. Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticarial. Pharmacogenomics. 2009 Mar;10(3):375-383. DOI: 10.2217/14622416.10.3.375
49. Guo A., Zhu W., Zhang C., et al. Association of FCER1A genetic polymorphisms with risk for chronic spontaneous urticaria and efficacy of nonsedating H1-antihistamines in Chinese patients. Arch Dermatol Res. 2015 Mar;307(2):183-190. DOI: 10.1007/s00403-014-1525-z
50. Imanaga J., Kotegawa T., Imai H., et al. The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. PharmacogenetGenomics. 2011 Feb;21(2): 84-93.
51. Yan S., Chen W., Wen S., et al. Influence of component 5a receptor 1 (C5AR1) -1330T/G. polymorphism on nonsedating H1-antihistamines therapy in Chinese patients with chronic spontaneous urticaria. J. Dermatol Sci. 2014 Dec;76(3):240-295. DOI: 10.1016/j.jdermsci.2014.09.012
Review
For citations:
Zastrozhina A.K., Suchev D.A. Pharmacogenetic aspects of the efficacy and safety profile of H1-histamine receptor blockers in the treatment of allergic diseases. Pharmacogenetics and Pharmacogenomics. 2018;(1):15-20. (In Russ.) https://doi.org/ 10.24411/2588-0527-2018-10003
Views:
967
Email this article 
Post a Comment 